Bayer Aktiengesellschaft

Bayer Pharma Aktiengesellschaft

Bayer Healthcare Aktiengesellschaft

Gerhard Franckowiak

Matthias Schramm

Rainer Gross

Gunter Thomas

Martin Bechem

Michael Kayser

Horst Meyer

Jurgen Stoltefuss

Friedrich Bossert

Gunther Thomas

Siegfried Goldmann

Egbert Wehinger

Robertson Towart

Arend Heise

Elisabeth Perzborn

Stanislav Kazda

Kurt Stoepel

Friedel Seuter

Horst Boshagen

Wolfram Ledwoch

Albrecht Marhold

Ulrich Rosentreter

Siegbert Hebisch

Hans-Peter Wirges

Fred R Heiker

Gregor Leifker

Hubert Appolt

Wulf Vater

Rolf Grosser

Alfons Grunenberg

Joachim Hutter

Paul Naab

Howard-Paul Rounding

Herbert Diehl

Ahmed Hegasy

Rudolf Zerbes

Yutaka Hayauchi

Siegfried Hebisch

Wolfgang M Uck

Eberhard Schweinheim

Rango-Rao Kanikanti

Claus Gert Haase

The present invention relates to stable active compound complexes of salts of o-acetylsalicylic acid with basic amino acids and glycine, to a process for their preparation and to their use as medicaments.

Stable active compound complex of salts of o-acetylsalicylic acid with basic amino acids and glycine

The present invention relates to stable salts of O-acetylsalicylic acid with basic amino acids, a process for their preparation and their use as medicaments.

Stable salts of O-acetylsalicylic acid with basic amino acids

The present invention relates to a one-pot process for the preparation of 7-heterocyclyl-substituted 3-quinolonecarboxylic acid derivatives. They possess a strong anti-microbial effect. They include active compounds such as, for example, ofloxacin, ciprofloxacin or enrofloxacin.

One-pot process for the preparation of 3-quinolonecarboxylic acid

The invention relates to pharmaceutical preparations, containing a specific crystal modification (subsequently called 'modification II') of isopropyl-(2-methoxyethyl) 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate (nimodipine) and to a process for its preparation.

Pharmaceutical preparation containing a specific crystal modification of

The present invention relates to the use of 3-formyl-1,4-dihydropyridine derivatives as medicaments for the control of cardiovascular diseases, in particular of pathologically changed blood pressure and of cardiac insufficiency, new compounds and a process for their preparation.

Certain 3-formyl-1, 4-dihydropyridines and their pharmaceutical

Circulation-active dihydropyridines of the formula ##STR1## in which R.sup.1 is H, CN, NO.sub.2 or --COOR.sup.7,

Circulation-active dioxyalkylenearyl-dihydropyridines

Circulation-active fluoromethoxyphenyldihydropyridines of the formula ##STR1## in which X stands for hydrogen or fluorine and

Circulation-active fluoromethoxyphenyl dihydropyridine compounds

Circulation active nitrodihydropyridines of the formula ##STR1## in which R represents aryl which has 6 to 12 carbon atoms and can be substituted up to 4 times, identically or differently, by halogen, nitro, cyano, alkyl, alkoxy, alkylthio, in each case having up to 6 carbon atoms, trifluoromethyl, trifluoromethoxy, difluoromethoxy, trifluoromethylthio, difluoromethylenedioxy, trifluoroethylenedioxy or tetrafluoroethylenedioxy or by benzyl, benzyloxy or benzylthio, each of which is optionally substituted by halogen, nitro, cyano, trifuoromethyl, alkyl having up to 4 carbon atoms or alkoxy having up to 4 carbon atoms, or represents a heterocycle which is optionally substituted by halogen, phenyl or alkyl having up to 4 carbon atoms and is from the group consisting of pyrryl, thienyl, furyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, pyridyl, pyrimidyl, pyridazinyl, quinolyl, benzoxadiazolyl, chromenyl or thiochromenyl, and

[4-(6-Oxo-1,4,5,6-tetrahydro-3-pyridazinyl) anilino hexyl

A composition effective for treating circulation disorders comprises a mixture of ##STR1## wherein the variables can have varied meetings. I are inotropic and II are vasodilating but, whereas the ingredients in the combination would be expected to be antagonistic, they are reinforcing.

Mixture of different dihydropyridines

Cardioactive novel dihydropyridine ethers of the formula ##STR1## in which R.sup.1 -stands for cyano, nitro or for a -COOR.sup.5 group, wherein

Circulation-active dihydropyridine ethers

For the treatment of circulation disorders, the novel 5-nitro-1,4-dihydropyridines of the formula ##STR1## in which R represents C.sub.6 -C.sub.14 -aryl which can be mono- to pentasubstituted by identical or different substituents from the series comprising halogen, nitro, cyano, C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 -alkoxy, C.sub.1 -C.sub.6 -alkoxy, C.sub.1 -C.sub.6 -alkylthio, trifluoromethyl, trifluoromethoxy, difluoromethoxy, trifluoromethylthio and benzyl, benzyloxy or benzylthio optionally substituted by nitro, cyano, trifluoromethyl, C.sub.1 -C.sub.4 -alkyl or C.sub.1 -C.sub.4 -alkoxy, or

Circulation-active substituted 5-nitro-1,4-dihydropyridines

For the control of coronary diseases and thromboses there are provided the novel compounds ##STR1## in which R.sup.1 is an optionally substituted phenyl or heterocyclic radical,

Substituted 1,4-dihydropyridines for control of circulation and

Novel circulation active dihydropyridines of the formula ##STR1## in which X is CO, SO.sub.2 or CONH,

Circulation-active 1,4-dihydropyridines

Growing community of inventors

Wuppertal, Germany

Gerhard Franckowiak